LATEST NEWS

Sep-21-2018

Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease

Preliminary Results Indicate Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal®) to pegunigalsidase alfa (PRX-102) A deterioration trend in patients’ kidney function on agalsidase alfa (Replagal®) was reversed to an improvement trend when switched to pegunigalsidase alfa (PRX-102)  Presentation with full Data to be held at the1st Canadian Symposium on Lysosomal Diseases 2018 CARMIEL, Israel, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (... 
Sep-17-2018

Protalix BioTherapeutics to Present Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018

~Oral Presentation to Include preliminary Kidney Function Data from First 16 Patients Enrolled~ CARMIEL, Israel, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that the Company will present preliminary data from the BRIDGE study of peg... 
Aug-23-2018

Protalix BioTherapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

CARMIEL, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that the Company will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conferenc... 
All News